- Home
- NTHI vs ENLV Comparison
NTHI vs ENLV Comparison
Compare NTHI & ENLV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NTHI | ENLV |
|---|---|---|
| Founded | 2008 | 2005 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 243.9M | 258.7M |
| IPO Year | N/A | 2014 |
Fundamental Metrics
Financial Performance| Metric | NTHI | ENLV |
|---|---|---|
| Price | $7.98 | $1.09 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $13.00 |
| AVG Volume (30 Days) | 26.8K | ★ 209.2K |
| Earning Date | 02-23-2026 | 04-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.20 | $0.66 |
| 52 Week High | $16.00 | $2.10 |
Technical Indicators
Market Signals| Indicator | NTHI | ENLV |
|---|---|---|
| Relative Strength Index (RSI) | 39.34 | 49.39 |
| Support Level | $5.25 | $1.00 |
| Resistance Level | $10.52 | $1.23 |
| Average True Range (ATR) | 0.70 | 0.06 |
| MACD | -0.18 | -0.01 |
| Stochastic Oscillator | 25.52 | 42.42 |
Price Performance
Historical ComparisonAbout NTHI NeOnc Technologies Holdings Inc.
NeOnc Technologies Holdings Inc. is the developer of a novel molecular technology that provides enhanced targeted delivery of technologies for treating central nervous system diseases. The company product includes NEO100, which commenced Phase 2a clinical trials, which is used for treating glioblastoma, and has Orphan Drug and Fast Track designation from the United States Food and Drug Administration (FDA).
About ENLV Enlivex Therapeutics Ltd.
Enlivex Ltd is a clinical stage macrophage reprogramming immunotherapy company currently focused on the late-stage clinical development of Allocetra, a novel therapy designed to treat the joint disease osteoarthritis. Additionally, it has developed a treasury using the RAIN protocol, which currently serves as the primary treasury reserve asset of the company.